Evidence map›Paper›PMID 34663385›Full record

ArticleChinese medicine2021

The therapeutic promises of Lianhuaqingke in the mice model of coronavirus pneumonia (HCoV-229E and SARS-CoV-2).

Mingye Wang, Wenyan Li, Wenwen Cui, Yuanyuan Hao, Yao Mi, Hongtao Wang, Yunlong Hou, Zhenhua Jia

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chinese medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Drugs against broad-spectrum of coronaviruses.Frontiers in immunology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mingye WangCollege of Integrated Traditional Chinese and Western Medicine, Hebei Medical University of Chinese Medicine, No.326, The South of Xinshi Street, Shijiazhuang, 050091, Hebei, China.
Wenyan LiShijiazhuang Yiling Pharmaceutical Co., Ltd, No.238, The South of Tianshan Street, Shijiazhuang, 050035, Hebei, China.
Wenwen CuiCollege of Integrated Traditional Chinese and Western Medicine, Hebei Medical University of Chinese Medicine, No.326, The South of Xinshi Street, Shijiazhuang, 050091, Hebei, China.
Yuanyuan HaoCollege of Integrated Traditional Chinese and Western Medicine, Hebei Medical University of Chinese Medicine, No.326, The South of Xinshi Street, Shijiazhuang, 050091, Hebei, China.
Yao MiShijiazhuang Yiling Pharmaceutical Co., Ltd, No.238, The South of Tianshan Street, Shijiazhuang, 050035, Hebei, China.
Hongtao WangShijiazhuang Yiling Pharmaceutical Co., Ltd, No.238, The South of Tianshan Street, Shijiazhuang, 050035, Hebei, China.
Yunlong HouCollege of Integrated Traditional Chinese and Western Medicine, Hebei Medical University of Chinese Medicine, No.326, The South of Xinshi Street, Shijiazhuang, 050091, Hebei, China. houyunlonghrb@hotmail.com.ORCID http://orcid.org/0000-0002-6989-8221
Zhenhua JiaShijiazhuang Yiling Pharmaceutical Co., Ltd, No.238, The South of Tianshan Street, Shijiazhuang, 050035, Hebei, China. jzhjiazhenhua@163.com.
Hebei Medical University · CNShijiazhuang Yiling Pharmaceutical (China) · CNHebei Yiling Hospital · CN

Funding

the key research and development program of hebei province 20372504Dthe post performance subsidy for luobing laboratory in hebei province 20567627H
6 · The paper itself

Abstract

backgroundLianhuaqingke (LHQK) has been approved for the treatment of acute tracheobronchitis and exerts a broad-spectrum antiviral effect in our previous study.

methodsAcute pneumonia caused by HCoV-229E was modeled in BALB/c mice. The anti-viral effect of LHQK was assessed by measuring the lung index and virus titer of lung tissues. The expression levels of pro-inflammatory cytokines in lung tissues and peripheral blood were measured by ELISA. The morphological changes of lung tissues were observed by H&E staining. The subsets of Th cells were assayed by the flow cytometry, including Th0, Th1, Th2, Treg, and Th17. The expression level of MUC5AC in 16HBE cells treated with TNFα was measured by ELISA. Immunofluorescence staining for β-IV tubulin was used to identify the airway epithelial ciliary in the condition-cultured RTE cells treated with TNFα. The direct antiviral effect of LHQK was assessed in vitro in Vero E6 infected by SARS-CoV-2, validated in vivo in the COVID-19 model of hACE2 transgenic mouse by detecting the lung index, the SARS-CoV-2 virus load, and the morphological changes of lung tissues.

resultsLHQK reduced the weight loss and the lung index by inhibiting the HCoV-229E replication and reducing the expression of pro-inflammatory cytokines in lung tissues. An assay for the Th cell subsets in peripheral blood revealed that LHQK could reduce the ratio of Th1/Th2 and increase the Treg/Th17 ratio in a dose-dependent way, which indicated that LHQK could coordinate the Th-mediated immune responses against the virus. In in vitro injury by TNFα, LHQK inhibited MUC5AC expression in 16HBE cells and increased the number of β-IV tubulin positive staining cells in the condition-cultured RTE cells. In the SARS-CoV-2-infected mice, LHQK could reduce weight loss, inhibit viral replication, and alleviate lung tissue damage.

conclusionsOur results demonstrate that LHQK exerts therapeutic effects on pneumonia caused by HCoVs (HCoV-229E and SARS-CoV-2) in mice, and that the anti-HCoV effects might depend on its immunomodulatory capacities. All these results suggest that LHQK serves as a potential adjuvant for anti-HCoV therapies.

Indexed as

Anti-HCoVs therapyHuman coronaviruses (HCoVs)ImmunomodulationLianhuaqingke (LHQK)

Identifiers

PMID34663385
PMCPMC8521501
OpenAlexW3206478918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.